<!DOCTYPE html>
<html lang="en" dir="ltr">
    <head>
        <meta charset="utf-8">
        <link rel="stylesheet" href="/static/rendered_html/uslm.css">
        <link rel="stylesheet" href="/static/rendered_html/style.css">
        <script src="https://kit.fontawesome.com/2ce1080035.js" crossorigin="anonymous"></script>
        <script lang="text/javascript" src="/static/rendered_html/omni.js" defer></script>

        <!-- Table of Contents button section sheet. Would ideally be a working breadcrumb --> 
        <ul class="breadcrumb" style="text-align:center">
            <!-- TODO GENERALIZE THIS --> 
            <li><a href="index.html"> Table of Contents</a></li>
            
                <li> Division A </a></li>
            
                <li> Title III </a></li>
            
                <li> Subtitle F </a></li>
            
                <li> Part I </a></li>
            
                <li> Section 3854 </a></li>
            
        </ul>


        <title> Omnibuster </title>

    </head>

    <body>
        <div class="section">
            <div class="buttons">
                <div class="navbar">
                    <div>
                        <button onclick="highlightSelection();">Highlight Text</button>
                    </div>
                    <div>
                        <button onclick="annotateSelection();">[Not working] Annotate Text</button>
                    </div> 
                </div>
            </div>
            <p> 
                <button class="collapsible"> Collapse </button><section id="d3355e27924" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854" style="-uslm-lc:I650144"><num value="3854">SEC. 3854. </num><heading>TREATMENT OF SUNSCREEN INNOVATION ACT.</heading><subsection class="indent0 fontsize10" id="d3355e27929" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/a" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="a">(a) </num><heading><inline class="small-caps">Review of Nonprescription Sunscreen Active Ingredients</inline>.—</heading><paragraph class="indent1 fontsize10" id="d3355e27936" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/a/1" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">(1) </num><heading><inline class="small-caps">Applicability of section 505g for pending submissions</inline>.—</heading><subparagraph class="indent2 fontsize10" id="d3355e27943" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/a/1/A" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>A sponsor of a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients that, as of the date of enactment of this Act, is subject to a proposed sunscreen order under section 586C of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff–3&amp;num=0&amp;edition=prelim"><ref href="/us/usc/t21/s360fff–3">21 U.S.C. 360fff–3</ref></a>) may elect, by means of giving written notification to the Secretary of Health and Human Services within 180 calendar days of the enactment of this Act, to transition into the review of such ingredient or combination of ingredients pursuant to the process set out in section 505G of the Federal Food, Drug, and Cosmetic Act, as added by section 3851 of this subtitle.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e27957" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/a/1/B" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">(B) </num><heading><inline class="small-caps">Election exercised</inline>.—</heading><chapeau>Upon receipt by the Secretary of Health and Human Services of a timely notification under subparagraph (A)—</chapeau><clause class="indent3 fontsize10" id="d3355e27966" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/a/1/B/i" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">(i) </num><content>the proposed sunscreen order involved is deemed to be a request for an order under subsection (b) of section 505G of the Federal Food, Drug, and Cosmetic Act, as added by section 3851 of this subtitle; and</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e27973" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/a/1/B/ii" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">(ii) </num><content>such order is deemed to have been accepted for filing under subsection (b)(6)(A)(i) of such section 505G.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e27981" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/a/1/C" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">(C) </num><heading><inline class="small-caps">Election not exercised</inline>.—</heading><chapeau>If a notification under subparagraph (A) is not received by the Secretary of Health and Human Services within 180 calendar days of the date of enactment of this Act, the review of the proposed sunscreen order described in subparagraph (A)—</chapeau><clause class="indent3 fontsize10" id="d3355e27990" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/a/1/C/i" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">(i) </num><content>shall continue under section 586C of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff–3&amp;num=0&amp;edition=prelim"><ref href="/us/usc/t21/s360fff–3">21 U.S.C. 360fff–3</ref></a>); and</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e28000" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/a/1/C/ii" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">(ii) </num><content>shall not be eligible for review under section 505G, added by section 3851 of this subtitle.</content>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e28009" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/a/2" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">(2) </num><heading><inline class="small-caps">Definitions</inline>.—</heading><content>In this subsection, the terms “sponsor”, “nonprescription”, “sunscreen active ingredient”, and “proposed sunscreen order” have the meanings given to those terms in section 586 of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff&amp;num=0&amp;edition=prelim"><ref href="/us/usc/t21/s360fff">21 U.S.C. 360fff</ref></a>).</content>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e28024" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/b" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="b">(b) </num><heading><inline class="small-caps">Amendments to Sunscreen Provisions</inline>.—</heading><paragraph class="indent1 fontsize10" id="d3355e28031" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/b/1" role="instruction" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">(1) </num><heading><inline class="small-caps">Final sunscreen orders</inline>.—</heading><content>Paragraph (3) of section 586C(e) of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff–3&amp;num=0&amp;edition=prelim"><ref href="/us/usc/t21/s360fff–3/e">21 U.S.C. 360fff–3(e)</ref></a>) <amendingAction type="amend">is amended</amendingAction> to read as follows:<quotedContent><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><heading><inline class="small-caps">Relationship to orders under section 505g</inline>.—</heading><content>A final sunscreen order shall be deemed to be a final order under section 505G.”</content>
</paragraph>
</quotedContent>.</content>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e28061" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/b/2" role="instruction" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">(2) </num><heading><inline class="small-caps">Meetings</inline>.—</heading><chapeau>Paragraph (7) of section 586C(b) of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff–3&amp;num=0&amp;edition=prelim"><ref href="/us/usc/t21/s360fff–3/b">21 U.S.C. 360fff–3(b)</ref></a>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><subparagraph class="indent2 fontsize10" id="d3355e28076" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/b/2/A" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">(A) </num><content>by <amendingAction type="delete">striking</amendingAction> “<quotedText>A sponsor may request</quotedText>” and <amendingAction type="insert">inserting</amendingAction> the following:<quotedContent><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>A sponsor may request”</content>
</subparagraph>
</quotedContent>; and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e28102" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/b/2/B" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">(B) </num><content>by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Confidential meetings</inline>.—</heading><content>A sponsor may request one or more confidential meetings with respect to a proposed sunscreen order, including a letter deemed to be a proposed sunscreen order under paragraph (3), to discuss matters relating to data requirements to support a general recognition of safety and effectiveness involving confidential information and public information related to such proposed sunscreen order, as appropriate. The Secretary shall convene a confidential meeting with such sponsor in a reasonable time period. If a sponsor requests more than one confidential meeting for the same proposed sunscreen order, the Secretary may refuse to grant an additional confidential meeting request if the Secretary determines that such additional confidential meeting is not reasonably necessary for the sponsor to advance its proposed sunscreen order, or if the request for a confidential meeting fails to include sufficient information upon which to base a substantive discussion. The Secretary shall publish a post-meeting summary of each confidential meeting under this subparagraph that does not disclose confidential commercial information or trade secrets. This subparagraph does not authorize the disclosure of confidential commercial information or trade secrets subject to 552(b)(4) of <ref href="/us/usc/t5">title 5, United States Code</ref>, or <a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title18-section1905&amp;num=0&amp;edition=prelim"><ref href="/us/usc/t18/s1905">section 1905 of title 18, United States Code</ref></a>.”</content>
</subparagraph>
</quotedContent>.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e28132" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/b/3" role="instruction" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">(3) </num><heading><inline class="small-caps">Exclusivity</inline>.—</heading><content>Section 586C of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff–3&amp;num=0&amp;edition=prelim"><ref href="/us/usc/t21/s360fff–3">21 U.S.C. 360fff–3</ref></a>) <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="f">“(f) </num><heading><inline class="small-caps">Exclusivity</inline>.—</heading><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>A final sunscreen order shall have the effect of authorizing solely the order requestor (or the licensees, assignees, or successors in interest of such requestor with respect to the subject of such request and listed under paragraph (5)) for a period of 18 months, to market a sunscreen ingredient under this section incorporating changes described in paragraph (2) subject to the limitations under paragraph (4), beginning on the date the requestor (or any licensees, assignees, or successors in interest of such requestor with respect to the subject of such request and listed under paragraph (5)) may lawfully market such sunscreen ingredient pursuant to the order.</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><heading><inline class="small-caps">Changes described</inline>.—</heading><content>A change described in this paragraph is a change subject to an order specified in paragraph (1) that permits a sunscreen to contain an active sunscreen ingredient not previously incorporated in a marketed sunscreen listed in paragraph (3).</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><heading><inline class="small-caps">Marketed sunscreen</inline>.—</heading><chapeau>The marketed sunscreen ingredients described in this paragraph are sunscreen ingredients—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>marketed in accordance with a final monograph for sunscreen drug products set forth at <a href="https://www.law.cornell.edu/cfr/text/21/t352"><ref href="/us/cfr/t21/pt352">part 352 of title 21, Code of Federal Regulations</ref></a> (as published at <ref href="/us/fr/64/27687">64 Fed. Reg. 27687</ref>); or</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>marketed in accordance with a final order issued under this section.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="4">“(4) </num><heading><inline class="small-caps">Limitations on exclusivity</inline>.—</heading><content>Only one 18-month period may be granted per ingredient under paragraph (1).</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="5">“(5) </num><heading><inline class="small-caps">Listing of licensees, assignees, or successors in interest</inline>.—</heading><content>Requestors shall submit to the Secretary at the time when a drug subject to such request is introduced or delivered for introduction into interstate commerce, a list of licensees, assignees, or successors in interest under paragraph (1).”</content>
</paragraph>
</subsection>
</quotedContent>.</content>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e28236" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/b/4" role="instruction" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="4">(4) </num><heading><inline class="small-caps">Sunset provision</inline>.—</heading><content>Subchapter I of chapter V of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff&amp;num=0&amp;edition=prelim"><ref href="/us/usc/t21/s360fff/etseq">21 U.S.C. 360fff et seq.</ref></a>) <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><section style="-uslm-lc:I650144"><num class="bold " value="586H">“SEC. 586H. </num><heading class="bold ">SUNSET.</heading><content class="indent0 fontsize10" style="-uslm-lc:I650120">  “This subchapter shall cease to be effective at the end of fiscal year 2022.”</content>
</section>
</quotedContent>.</content>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e28268" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/b/5" role="instruction" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="5">(5) </num><heading><inline class="small-caps">Treatment of final sunscreen order</inline>.—</heading><content>The Federal Food, Drug, and Cosmetic Act <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="delete">striking</amendingAction> section 586E of such Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff–5&amp;num=0&amp;edition=prelim"><ref href="/us/usc/t21/s360fff–5">21 U.S.C. 360fff–5</ref></a>).</content>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e28289" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/c" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="c">(c) </num><heading><inline class="small-caps">Treatment of Authority Regarding Finalization of Sunscreen Monograph</inline>.—</heading><paragraph class="indent1 fontsize10" id="d3355e28296" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/c/1" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">(1) </num><heading><inline class="small-caps">In general</inline>.—</heading><subparagraph class="indent2 fontsize10" id="d3355e28303" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/c/1/A" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">(A) </num><heading><inline class="small-caps">Revision of final sunscreen order</inline>.—</heading><content>The Secretary of Health and Human Services (referred to in this subsection as the “Secretary”) shall amend and revise the final administrative order concerning nonprescription sunscreen (referred to in this subsection as the “sunscreen order”) for which the content, prior to the date of enactment of this Act, was represented by the final monograph for sunscreen drug products set forth in <a href="https://www.law.cornell.edu/cfr/text/21/t352"><ref href="/us/cfr/t21/pt352">part 352 of title 21, Code of Federal Regulations</ref></a> (as in effect on May 21, 1999).</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e28317" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/c/1/B" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">(B) </num><heading><inline class="small-caps">Issuance of revised sunscreen order; effective date</inline>.—</heading><chapeau>A revised sunscreen order described in subparagraph (A) shall be—</chapeau><clause class="indent3 fontsize10" id="d3355e28326" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/c/1/B/i" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">(i) </num><content>issued in accordance with the procedures described in section 505G(b)(2) of the Federal Food, Drug, and Cosmetic Act;</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e28333" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/c/1/B/ii" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">(ii) </num><content>issued in proposed form not later than 18 months after the date of enactment of this Act; and</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e28340" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/c/1/B/iii" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">(iii) </num><content>issued by the Secretary at least 1 year prior to the effective date of the revised order.</content>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e28349" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/c/2" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">(2) </num><heading><inline class="small-caps">Reports</inline>.—</heading><content>If a revised sunscreen order issued under paragraph (1) does not include provisions related to the effectiveness of various sun protection factor levels, and does not address all dosage forms known to the Secretary to be used in sunscreens marketed in the United States without a new drug application approved under section 505 of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355&amp;num=0&amp;edition=prelim"><ref href="/us/usc/t21/s355">21 U.S.C. 355</ref></a>), the Secretary shall submit a report to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate on the rationale for omission of such provisions from such order, and a plan and timeline to compile any information necessary to address such provisions through such order.</content>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e28364" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/d" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="d">(d) </num><heading><inline class="small-caps">Treatment of Non-Sunscreen Time and Extent Applications</inline>.—</heading><paragraph class="indent1 fontsize10" id="d3355e28371" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/d/1" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">(1) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>Any application described in section 586F of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff–6&amp;num=0&amp;edition=prelim"><ref href="/us/usc/t21/s360fff–6">21 U.S.C. 360fff–6</ref></a>) that was submitted to the Secretary pursuant to <a href="https://www.law.cornell.edu/cfr/text/21/330.14"><ref href="/us/cfr/t21/s330.14">section 330.14 of title 21, Code of Federal Regulations</ref></a>, as such provisions were in effect immediately prior to the date of enactment date of this Act, shall be extinguished as of such date of enactment, subject to paragraph (2).</content>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e28388" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3854/d/2" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">(2) </num><heading><inline class="small-caps">Order request</inline>.—</heading><content>Nothing in paragraph (1) precludes the submission of an order request under section 505G(b) of the Federal Food, Drug, and Cosmetic Act, as added by section 3851 of this subtitle, with respect to a drug that was the subject of an application extinguished under paragraph (1).</content>
</paragraph>
</subsection>
</section>
            </p>
        </div>  

        <!-- previous section -->
        <button onclick="location.href='section_s3853.html'" id="ls-btn-prev-sec" title="go to previous section">
            <i class="fas fa-angle-left"></i>
        </button>
        <!-- end previous section -->

        <!-- next section -->
        <button onclick="location.href='section_s3855.html'" id="ls-btn-next-sec" title="go to next section" data-ls-target-index="2">
            <i class="fas fa-angle-right"></i>
        </button>
        <!-- end next section -->

    </body>
